What Happened?
Boston, MA-based Sensei-Biotherapeutics Promoted Robert Pierce as Chief Research and Development Officer
About the Company
Driven by world class scientists and an entrepreneurial culture focused on rigorous science, innovative treatments, and data-driven decision making, we discover and develop medicines that have the potential to alter the treatment landscape and contribute value to patients and society. The company has developed a unique drug discovery approach, ImmunoPhage™️, that generates powerful and specific immune responses. Its most advanced program, SNS-301, is currently enrolling patients in Phase 1/2 clinical trials.
About the Person
Robert Pierce is Chief Research and Development Officer at Sensei Biotherapeutics. Previously, Robert held various senior HR leadership roles in the industry.
Info Source
News
Short Profile